The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
Name: Daclatasvir
Description: Tablet, Oral, 60 mg, once daily, 24 weeksType: DrugArm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin
Name: Peg-Interferon Alfa-2a
Description: Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on responseType: DrugArm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin
Name: Ribavirin
Description: Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on responseType: DrugArm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin
Description: SVR12 was defined as Hepatitis C Virus (HCV) RNA levels
Description: SVR12 was defined as Hepatitis C Virus (HCV) RNA levels
Description: The limit of detection for HCV RNA levels was 10 IU/mL and the LLOQ was 25 IU/mL. Data for post-treatment Weeks 36 and 48 were based on participants who had achieved virologic response (defined as HCV RNA levels Description: The limit of detection for HCV RNA levels was 10 IU/mL and the LLOQ was 25 IU/mL. For analysis purpose, participants were assigned to following 3 race/ethnicity cohorts: Black/African American, Latino, and White non-Latino. Some participants were represented in more than one race/ethnicity cohort. Description: An AE was defined as any new unfavorable symptom, sign, or disease or worsening of a pre-existing condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Treatment-related AE was defined as an AE that had certain, probable, possible, or unknown relationship to study drug. For analysis purpose, participants were assigned to following 4 race/ethnicity cohorts: Black/African American, White/Caucasian, Latino and Non-Latino. Some participants were represented in more than one race/ethnicity cohort.
Single Group Assignment
There is one SNP
Some participants were represented in more than one race/ethnicity cohort.. Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene.